Compass Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Compass Therapeutics
CMPX Stock  USD 3.11  0.11  3.42%   
Compass Therapeutics financial statements provide useful quarterly and yearly information to potential Compass Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Compass Therapeutics financial statements helps investors assess Compass Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Compass Therapeutics' valuation are summarized below:
Gross Profit
850 K
Market Capitalization
415.5 M
Enterprise Value Revenue
337.6403
Revenue
850 K
Earnings Share
(0.35)
We have found one hundred twenty available fundamental signals for Compass Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Compass Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Interest Income of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.26. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Compass Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets120.5 M180.4 M92.2 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.6 M10.5 M
Slightly volatile
Total Current Liabilities11.5 M9 M9.5 M
Slightly volatile
Property Plant And Equipment Net3.2 M2.4 M4.5 M
Slightly volatile
Current Deferred Revenue2 M3.6 M1.6 M
Slightly volatile
Accounts Payable4.9 M4.7 M2.2 M
Slightly volatile
Cash20.7 M21.8 M52.3 M
Pretty Stable
Non Current Assets Total3.5 M2.7 M4.9 M
Slightly volatile
Non Currrent Assets Other327.4 K368 K343.6 K
Slightly volatile
Long Term Debt1.6 M1.7 M7.5 M
Slightly volatile
Cash And Short Term Investments112.5 M175.3 M85.1 M
Slightly volatile
Common Stock Total Equity11.1 K11.7 K1.6 M
Slightly volatile
Common Stock Shares Outstanding78.8 M146.1 M67 M
Slightly volatile
Liabilities And Stockholders Equity120.5 M180.4 M92.2 M
Slightly volatile
Non Current Liabilities Total458.3 K482.4 K88.5 M
Slightly volatile
Other Current Assets3.2 M1.6 M2.1 M
Slightly volatile
Other Stockholder Equity273.3 M533.4 M145.7 M
Slightly volatile
Total Liabilities7.1 M7.5 M97.5 M
Slightly volatile
Property Plant And Equipment Gross7.5 M10.3 M6.3 M
Slightly volatile
Short and Long Term Debt6.1 M8.6 M5.2 M
Slightly volatile
Total Current Assets115.7 M177 M87.2 M
Slightly volatile
Capital Stock11.1 K11.7 K1.6 M
Slightly volatile
Net Working Capital104.2 M168 M77.7 M
Slightly volatile
Short Term Debt1 M1.1 M3.2 M
Slightly volatile
Common Stock11.1 K11.7 K1.6 M
Slightly volatile
Property Plant Equipment1.3 M1.4 M4.1 M
Slightly volatile
Long Term Debt Total1.5 M1.7 M1.8 M
Slightly volatile
Capital Surpluse373.9 M523 M267.8 M
Slightly volatile
Non Current Liabilities Other2.4 M2.7 M3 M
Slightly volatile
Net Receivables256 K288 K314 K
Slightly volatile

Compass Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income9.5 M9 M2.2 M
Slightly volatile
Depreciation And Amortization1.7 M1.7 M2 M
Very volatile
Interest Expense2.8 M2.7 M1.2 M
Slightly volatile
Selling General Administrative12.9 M14.1 M11.7 M
Slightly volatile
Other Operating Expenses41 M57.9 M39.3 M
Slightly volatile
Research Development27.9 M43 M27.5 M
Pretty Stable
Total Operating Expenses40.6 M55.7 M39 M
Slightly volatile
Reconciled Depreciation1.6 M1.7 M1.9 M
Slightly volatile
Cost Of Revenue1.6 M1.7 M2 M
Slightly volatile
Selling And Marketing Expenses8.8 M9.9 M10.8 M
Slightly volatile

Compass Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M7 M2.3 M
Slightly volatile
Begin Period Cash Flow62.3 M40.2 M42.3 M
Slightly volatile
Depreciation1.6 M1.7 M1.9 M
Slightly volatile
Capital Expenditures25.6 K27 K1.3 M
Slightly volatile
Issuance Of Capital Stock2.7 M2.8 M48.6 M
Pretty Stable
Total Cash From Financing Activities2.5 M2.6 M51.7 M
Slightly volatile
End Period Cash Flow20.7 M21.8 M52.4 M
Pretty Stable
Change To Netincome5.7 M6 M5.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.01730.01830.6785
Slightly volatile
Payables Turnover0.50.531.2224
Very volatile
Cash Per Share1.121.081.2138
Slightly volatile
Days Payables Outstanding746711395
Slightly volatile
Income Quality0.871.10.8609
Very volatile
Net Debt To EBITDA0.40.421.2175
Very volatile
Current Ratio18.6417.759.5153
Slightly volatile
Graham Number5.73.415.1051
Pretty Stable
Capex Per Share3.0E-43.0E-40.0243
Slightly volatile
Interest Debt Per Share0.01490.01570.2179
Slightly volatile
Debt To Assets0.01210.01270.175
Slightly volatile
Days Of Payables Outstanding746711395
Slightly volatile
Ebt Per Ebit1.080.970.9929
Pretty Stable
Quick Ratio18.6417.759.5153
Slightly volatile
Net Income Per E B T1.091.081.0049
Pretty Stable
Cash Ratio6.033.576.0528
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0578
Pretty Stable
Debt Ratio0.01210.01270.175
Slightly volatile

Compass Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap354.4 M398.7 M434.6 M
Slightly volatile
Enterprise Value333.1 M389.3 M405.4 M
Very volatile

Compass Fundamental Market Drivers

Cash And Short Term Investments152.5 M

Compass Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M2 M
Cost Of Revenue1.7 M1.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
SSentinelOne

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY